[7][8] In 2018, the company introduced Deep Genome AI, which uses artificial intelligence to interpret and store genetic research data, accelerating the development of gene-based products.

[9][10] In 2019, firm's operations expanded due to the COVID-19 crisis,[11][12] emerging as Austria's largest COVID-19 laboratory, conducting up to 275,000 tests daily and producing millions of medical devices for sample collection.

[17][18] In December 2021, Novogenia GmbH underwent an Initial Public Offering (IPO) on the Munich stock exchange under DARWIN AG, a biotechnology group of companies.

[25] Novogenia specializes in creating personalized food supplements through advanced blood and genetic analysis, tailoring blends of micronutrients to each customer's needs for optimized health support.

[26] It's approach offers over 700 trillion possible formulations based on genetic analyses, employing a specialized algorithm to ensure personalized nutrient recipes within safety limits.